Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasoconstriction evaluation of Wynzora (MC2-01) cream
NCT03758365Phase 1Completed
- Sponsor
- MC2 Therapeutics
- Start
- Nov 2018
- Primary completion
- Nov 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AKP01 and betamethasone dipropionate spray 0.05% in plaque psoriasis (7 arms), sponsored by MC2 Therapeutics. Primary endpoints: Vasoconstriction Potential (Skin Blanching Effect) at Day 2 and Local Tolerability at Day 2. Started Nov 2018; status: completed.
02
Drugs
AKP01betamethasone dipropionate spray 0.05%
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03758365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758365.